In HCC and other cancers, mutations or abnormal expression of KEAP1 or NRF2 lead to sustained activation of this pathway, contributing to cancer cell survival, proliferation, and resistance to therapy [13,14]. The gene discussed is KEAP1; the disease is hepatocellular carcinoma.